pilot trial of visual healing® in psilocybin-assisted therapy for alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: twenty participants, age 18 or older, who meet diagnostic and statistical manual of mental disorders (dsm-5) criteria for moderate to severe alcohol use disorder will be randomized to open-label psilocybin (25 mg) therapy with the visual healing set and setting platform (n=10) versus psilocybin (25 mg) with a standard set and setting platform (n=10). the purpose of this study is to evaluate the feasibility, safety, and tolerability of adding visual healing, a nature-themed virtual immersive program, to psilocybin-assisted therapy among participants with alcohol use disorder.

the objective of the study is to test a strategy for optimizing set and setting for psilocybin-assisted therapy of alcohol use disorder. psilocybin shows promise in early trials for alcohol use disorder, but initial results suggest that patients with alcohol use disorder may be less likely to achieve a mystical experience with standard doses of psilocybin. optimizing set and setting for the psilocybin experience may improve outcomes without requiring higher drug doses. the current study will complete a pilot randomized clinical trial to assess the feasibility, safety, and tolerability of visual healing set and setting (n=10) versus standard set and setting procedures (n=10) in participants with alcohol use disorder undergoing open-label psilocybin 25 mg therapy. in the visual healing condition, participants will view nature-themed video programs during the prep session and during the ascent phase of the psilocybin experience. anecdotal reports and reviews suggest that viewing visual healing creates a tranquil and calming environment that fosters a stronger connection between the viewer and nature. psilocybin increases the users feeling of connection to nature and having an intention to connect with nature during the psychedelic session is associated with better outcomes of psychedelic-assisted therapy in initial studies. reducing pre-dosing anxiety/apprehension and enhancing connections to nature with visual healing may improve outcomes of psychedelic-assisted therapy without the need for higher psilocybin doses.

Eligibility criteria:
inclusion criteria: * age 18 or older * able to read, speak, and understand english * alcohol use disorder, moderate-severe, according to dsm-5 criteria * interested in stopping or reducing alcohol use * able and willing to adhere to study requirements, including attending all study visits, preparatory, and follow-up sessions, and completing all study evaluations * able to swallow capsules * women of childbearing potential (wocbp) must agree to practice an effective means of birth control throughout the duration of the study * have an identified support person * agree to be driven home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing exclusion criteria: * alcohol withdrawal requiring medical intervention * women who are pregnant, or women who intend to become pregnant during the study or who are currently nursing * unwilling or unable to discontinue formal alcohol use disorder treatment * significant current or history of cardiovascular condition * have a history of stroke or transient ischemic attack (tia) * moderate to severe liver impairment * epilepsy * insulin-dependent diabetes * diabetes and taking oral hypoglycemic agent with a history of hypoglycemia requiring serious medical intervention

Keywords: psilocybin psychedelics alcohol use disorder alcoholism psychedelic-assisted therapy